Supporto al caregiver culturalmente reattivo
Programmazione di supporto culturalmente reattivo per i caregiver neri di persone con demenza
Black family caregivers of older adults with Alzheimer's disease and/or related dementias (ADRD), have an increased mortality risk related to pre-existing health conditions and stress. Targeted, culturally responsive, health interventions that help Black ADRD caregivers to effectively manage their own health and use community preferenced ways of coping, can improve caregivers' overall health, perceived ability to provide care for a person with ADRD (self-efficacy), and increases the likelihood that they will experience benefits from caregiving. This clinical trial pilot will test the feasibility of a community based intervention designed to improve health outcomes for Black family caregivers of persons with ADRD.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The proposed intervention is a peer-supportive and facilitator-led video teleconference program that will engage small groups of caregivers weekly over 6 weeks. Each week participants (n = 36, 2-5/group) will receive a different culturally relevant caregiving or personal health strategy to practice. During the support calls, a facilitator will provide an overview of the content covered and each participant will have the opportunity to discuss their past week and how they engaged the weekly strategy, or challenges that came up for them during the week. The format will be structured to ensure that core content is reviewed, and everyone can be equally engaged while flexible enough that caregivers can receive support in the areas they need. A battery of assessment measures will be taken at weeks 1 and 8.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- University of Michigan
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria for participation are as follows:
Self-identified as Black/ African American At least 18 years old Able to speak, understand, and hear spoken English Related to, or has a close personal relationship to a person over the age of 55 that has an ADRD diagnosis or evidence of cognitive impairment Regular access to a smartphone, tablet or computer with internet access that will allow video conferencing engagement.
Provides monitoring, and assistance in activities of daily living and or other care tasks for the care recipient.
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Caregiver Support
All participants in all groups will receive 6 weeks of caregiving support including a weekly video/teleconference call, and handouts covering relevant educational topics) |
Caregivers engage in a weekly video/teleconference support group with a skilled facilitator to discuss various strategies for managing caregiving stress, challenging behaviors, and personal self-care. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Caregiver Self-efficacy for Obtaining Respite Care
Lasso di tempo: 6 weeks
|
Caregiver self-efficacy was measured using the Revised Scale for Caregiving Self-Efficacy at baseline and one week following the intervention. The scale assesses the level of confidence caregivers had in obtaining respite care, responding to disruptive behaviors, and controlling their own upsetting thoughts about caregiving, using a range of 0- 100, with 0 indicating not confident one could do the described task at all and 100 indicating certainty one could perform the described task. Outcomes report the average change from baseline. |
6 weeks
|
|
Caregiver Self-Efficacy for Controlling Upsetting Thoughts
Lasso di tempo: 6 Weeks
|
Caregiver self-efficacy was measured using the Revised Scale for Caregiving Self-Efficacy at baseline and one week following the intervention. The scale assesses the level of confidence caregivers had in obtaining respite care, responding to disruptive behaviors, and controlling their own upsetting thoughts about caregiving, using a range of 0- 100, with 0 indicating not confident one could do the described task at all and 100 indicating certainty one could perform the described task. Outcomes report the average change from baseline. |
6 Weeks
|
|
Caregiver Self-Efficacy for Responding to Disruptive Behaviors
Lasso di tempo: 6 Weeks
|
Caregiver self-efficacy was measured using the Revised Scale for Caregiving Self-Efficacy at baseline and one week following the intervention. The scale assesses the level of confidence caregivers had in obtaining respite care, responding to disruptive behaviors, and controlling their own upsetting thoughts about caregiving, using a range of 0- 100, with 0 indicating not confident one could do the described task at all and 100 indicating certainty one could perform the described task. Outcomes report the average change from baseline. |
6 Weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Positive Aspects of Caregiving
Lasso di tempo: 6 weeks
|
The Positive Aspects of Caregiving tool is a brief assessment measure that asks questions about caregiving experiences that made the caregiver feel good about providing care. Responses are rated from 1, disagree a lot, to 5, agree a lot. Scores range from 9 to 45 with higher scores indicating more positive experiences related to family caregiving. |
6 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HUM00230940
- 1K01AG065420-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
It is anticipated that the following data will be generated and made available 1) published tables, figures, graphs, and tables of data used for making graphs; 2) published journal papers, conference papers, annual reports and the final report; and 3) educational materials resulting from intervention development. All data will conform with relevant data and terminology standards.
Periodo di condivisione IPD
No less than 5 years following the date of the project completion or the date of study publication.
Criteri di accesso alla condivisione IPD
To facilitate data sharing, project data will be made publicly available via a university-managed repository Deep Blue.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .